Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by toinv261on Mar 15, 2014 4:35pm
128 Views
Post# 22327928

RE:RE:RE:RE:RE:Zenith

RE:RE:RE:RE:RE:ZenithHi Sanfran, Torpedoman,jk,kayak guy and others. Thanks to all for your helpful posts.

I can't be of any specific help here (wish I could) but I will reflect my thoughts.
  1. Just the fact that a (good) deal was done gave me tremendous relief. I had started to think that this company (both companies) were sort of lulling along in that Rocky Mountain air and lacked intense drive even though the science looks extremely promising.
  2. This investment reflects the continuing confidence of Eastern Capital and NGN BioMed that there really is solid science and that that science is/will be in demand by BP or other opportunities. This seems significant to me because they must be intimately involved with the knowledge of the science or at least the odds of success of the science.
  3. The depth and quality of scientific and capital markets knowledge within the full team - management, Eastern, NGN and the advisory boards - is remarkable.

I'm feeling good. It should be interesting times.

One question - There is a 4 month hold on the transaction (I think) which puts this to mid July for finalization. So I guess not much happens (outwardly) until at least then???

I offer my congratulations to Don and Dr. Wong and to their team.
Toinv
Bullboard Posts